Bristol-Myers Squibb Company (BMY) vs Gilead Sciences, Inc. (GILD)
GILD leads on 10 of 17 compared metrics, though BMY is the cheaper stock.
A side-by-side comparison of Bristol-Myers Squibb Company and Gilead Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 14, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
BMY
Bristol-Myers Squibb Company
$57.13Healthcare
GILD
Gilead Sciences, Inc.
$125.59Healthcare
Total return — BMY vs GILD
growth of $100 · last 30yBMY +171.1%GILD +14253.1%GILD compounded faster
Log scale — wide-divergence pair
BMY GILD
BMY vs GILD: by the numbers
- •GILD is the larger company ($155.93B vs $116.66B market cap).
- •BMY trades at the lower earnings multiple (16.05 vs 17.11 P/E).
- •GILD converts more revenue to profit (30.99% vs 15.01% net margin).
- •GILD grew revenue faster over the past five years (3.07% vs 2.52% CAGR).
- •BMY pays the higher dividend yield (4.38% vs 1.91%).
Which is better, BMY or GILD?
Metric tally: BMY 7 · GILD 10It depends on what you're optimizing for:
ValueBMY(lower P/E)
GrowthGILD(faster 5Y revenue CAGR)
IncomeBMY(higher dividend yield)
QualityGILD(higher ROIC)
Valuation
| Metric | BMY | GILD |
|---|---|---|
| P/E ratio | 16.05● | 17.11 |
| Forward P/E | 9.31● | 13.00 |
| P/S ratio | 2.41● | 5.30 |
| P/B ratio | 5.82● | 6.70 |
| PEG ratio | 1.71 | 0.01● |
| EV / EBITDA | 11.03● | 12.91 |
| FCF yield | 10.20%● | 6.49% |
Profitability
| Metric | BMY | GILD |
|---|---|---|
| Gross margin | 68.75% | 79.35%● |
| Operating margin | 25.67% | 38.26%● |
| Net margin | 15.01% | 30.99%● |
| ROE | 36.25% | 39.19%● |
| ROIC | 13.90% | 21.53%● |
Dividends
| Metric | BMY | GILD |
|---|---|---|
| Dividend yield | 4.38%● | 1.91% |
| Payout ratio | 72.25% | 35.09% |
Growth (annualized)
| Metric | BMY | GILD |
|---|---|---|
| Revenue CAGR (5Y) | 2.52% | 3.07%● |
| EPS CAGR (5Y) | 9.38% | 133.83%● |
| FCF CAGR (5Y) | -2.50% | 3.30%● |
| Total return CAGR (5Y) | 0.74% | 17.06%● |
Frequently asked
- Which is better, BMY or GILD?
- It depends on your goal. value: BMY (lower P/E); growth: GILD (faster 5Y revenue CAGR); income: BMY (higher dividend yield); quality: GILD (higher ROIC). Across all compared metrics, GILD leads 10 to 7.
- Is BMY or GILD cheaper?
- On trailing earnings, BMY is cheaper: BMY trades at a 16.05 P/E and GILD at 17.11.
- Which has grown faster, BMY or GILD?
- Over the past five years, GILD grew revenue faster — BMY at a 2.52% CAGR versus GILD at 3.07%.
- Does BMY or GILD pay a bigger dividend?
- BMY yields 4.38% and GILD yields 1.91% based on trailing dividends and the latest price.
- Is BMY or GILD more profitable?
- GILD runs the higher net margin — BMY at 15.01% versus GILD at 30.99%.
- Which has been the better investment, BMY or GILD?
- Over the past 10-year, GILD delivered the higher annualized total return — BMY at 1.08% versus GILD at 7.79%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioGilead Sciences P/E ratioBristol-Myers Squibb dividend yieldGilead Sciences dividend yieldBristol-Myers Squibb ROEGilead Sciences ROEBristol-Myers Squibb operating marginGilead Sciences operating marginBristol-Myers Squibb revenue growthGilead Sciences revenue growthBristol-Myers Squibb free cash flowGilead Sciences free cash flow
Bristol-Myers Squibb & Gilead Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 14, 2026.